Trevi Therapeutics, Inc. (TRVI)

US — Healthcare Sector
Peers: LIFE  CUE  ANTX  BCAB  SPRO  BOLT  CHRS  GRCL  NLTX  FHTX  CCCC  CYT  PRLD  RZLT  LYRA  SQZ  TARA  TCON  SEER  ORIC  ANEB  CGEM 

Automate Your Wheel Strategy on TRVI

With Tiblio's Option Bot, you can configure your own wheel strategy including TRVI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TRVI
  • Rev/Share 0.0
  • Book/Share 0.8456
  • PB 7.9702
  • Debt/Equity 0.0096
  • CurrentRatio 15.3832
  • ROIC -0.5084

 

  • MktCap 685761300.0
  • FreeCF/Share -0.3512
  • PFCF -16.604
  • PE -16.7416
  • Debt/Assets 0.0089
  • DivYield 0
  • ROE -0.5841

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation TRVI H.C. Wainwright -- Buy -- $21 May 28, 2025
Reiterated TRVI Needham -- Buy $8 $25 March 10, 2025
Upgrade TRVI Raymond James Outperform Strong Buy $9 $29 March 10, 2025
Reiterated TRVI H.C. Wainwright -- Buy $6 $7.5 Dec. 12, 2024
Resumed TRVI Leerink Partners -- Outperform $6 $7 Sept. 9, 2024
Initiation TRVI Raymond James -- Outperform -- $9 Aug. 30, 2024
Initiation TRVI H.C. Wainwright -- Buy -- $6 Aug. 30, 2024

News

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
TRVI
Published: June 02, 2025 by: Benzinga
Sentiment: Positive

Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).

Read More
image for news Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
TRVI
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral

Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p

Read More
image for news Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
TRVI
Published: June 01, 2025 by: PRNewsWire
Sentiment: Neutral

Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.

Read More
image for news Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
TRVI
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
TRVI
Published: March 10, 2025 by: Benzinga
Sentiment: Positive

On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).

Read More
image for news Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

About Trevi Therapeutics, Inc. (TRVI)

  • IPO Date 2019-05-07
  • Website https://www.trevitherapeutics.com
  • Industry Biotechnology
  • CEO Ms. Jennifer L. Good
  • Employees 31

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.